351 related articles for article (PubMed ID: 11160647)
1. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
2. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
3. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
4. The complexity of intestinal absorption and exsorption of digoxin in rats.
Yao HM; Chiou WL
Int J Pharm; 2006 Sep; 322(1-2):79-86. PubMed ID: 16781832
[TBL] [Abstract][Full Text] [Related]
5. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
7. Everted rat intestinal sacs: a new model for the quantitation of P-glycoprotein mediated-efflux of anticancer agents.
Carreño-Gómez B; Duncan R
Anticancer Res; 2000; 20(5A):3157-61. PubMed ID: 11062737
[TBL] [Abstract][Full Text] [Related]
8. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.
Collett A; Higgs NB; Sims E; Rowland M; Warhurst G
J Pharmacol Exp Ther; 1999 Jan; 288(1):171-8. PubMed ID: 9862768
[TBL] [Abstract][Full Text] [Related]
10. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
Okudaira N; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.
Makhey VD; Guo A; Norris DA; Hu P; Yan J; Sinko PJ
Pharm Res; 1998 Aug; 15(8):1160-7. PubMed ID: 9706044
[TBL] [Abstract][Full Text] [Related]
12. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ
Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995
[TBL] [Abstract][Full Text] [Related]
13. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.
González-Alvarez I; Fernández-Teruel C; Casabó-Alós VG; Garrigues TM; Polli JE; Ruiz-García A; Bermejo M
Biopharm Drug Dispos; 2007 Jul; 28(5):229-39. PubMed ID: 17410527
[TBL] [Abstract][Full Text] [Related]
14. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
15. Pumping of drugs by P-glycoprotein: a two-step process?
Litman T; Skovsgaard T; Stein WD
J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
[TBL] [Abstract][Full Text] [Related]
16. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs.
Sha X; Fang X
Int J Pharm; 2004 Mar; 272(1-2):161-71. PubMed ID: 15019079
[TBL] [Abstract][Full Text] [Related]
17. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
[TBL] [Abstract][Full Text] [Related]
18. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
19. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism.
Prueksaritanont T; DeLuna P; Gorham LM; Ma B; Cohn D; Pang J; Xu X; Leung K; Lin JH
Drug Metab Dispos; 1998 Jun; 26(6):520-7. PubMed ID: 9616186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
